Fungal Drug Discovery for Chronic Disease: History, New Discoveries and New Approaches

被引:29
作者
Prescott, Thomas A. K. [1 ]
Hill, Rowena [2 ]
Mas-Claret, Eduard [1 ]
Gaya, Ester [1 ]
Burns, Edie [1 ]
机构
[1] Royal Bot Gardens, Richmond TW9 3AB, Surrey, England
[2] Earlham Inst, Norwich NR4 7UZ, Norfolk, England
基金
英国生物技术与生命科学研究理事会;
关键词
fungi; drugs; self-resistance; ecological function; drug distribution; mechanism of action; PENICILLIUM-CHRYSOGENUM; METABOLIC PRODUCT; GANODERMA; MECHANISM; BIOSYNTHESIS; MUSHROOM; AGENT; ANTROQUINONOL; RESISTANCE; INHIBITOR;
D O I
10.3390/biom13060986
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fungal-derived drugs include some of the most important medicines ever discovered, and have proved pivotal in treating chronic diseases. Not only have they saved millions of lives, but they have in some cases changed perceptions of what is medically possible. However, now the low-hanging fruit have been discovered it has become much harder to make the kind of discoveries that have characterised past eras of fungal drug discovery. This may be about to change with new commercial players entering the market aiming to apply novel genomic tools to streamline the discovery process. This review examines the discovery history of approved fungal-derived drugs, and those currently in clinical trials for chronic diseases. For key molecules, we discuss their possible ecological functions in nature and how this relates to their use in human medicine. We show how the conservation of drug receptors between fungi and humans means that metabolites intended to inhibit competitor fungi often interact with human drug receptors, sometimes with unintended benefits. We also plot the distribution of drugs, antimicrobial compounds and psychoactive mushrooms onto a fungal tree and compare their distribution to those of all fungal metabolites. Finally, we examine the phenomenon of self-resistance and how this can be used to help predict metabolite mechanism of action and aid the drug discovery process.
引用
收藏
页数:25
相关论文
共 94 条
[1]  
ABRAHAM EP, 1979, REV INFECT DIS, V1, P99
[2]  
Adachi K, 2007, PERSPECT MED CHEM, V1, P11
[3]   MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT [J].
ALBERTS, AW ;
CHEN, J ;
KURON, G ;
HUNT, V ;
HUFF, J ;
HOFFMAN, C ;
ROTHROCK, J ;
LOPEZ, M ;
JOSHUA, H ;
HARRIS, E ;
PATCHETT, A ;
MONAGHAN, R ;
CURRIE, S ;
STAPLEY, E ;
ALBERSSCHONBERG, G ;
HENSENS, O ;
HIRSHFIELD, J ;
HOOGSTEEN, K ;
LIESCH, J ;
SPRINGER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07) :3957-3961
[4]   ANTIBIOTIC SUBSTANCES FROM BASIDIOMYCETES .7. CLITOCYBE ILLUDENS [J].
ANCHEL, M ;
HERVEY, A ;
ROBBINS, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1950, 36 (05) :300-305
[5]   Higher Mushroom Consumption Is Associated with Lower Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies [J].
Ba, Djibril M. ;
Ssentongo, Paddy ;
Beelman, Robert B. ;
Muscat, Joshua ;
Gao, Xiang ;
Richie, John P., Jr. .
ADVANCES IN NUTRITION, 2021, 12 (05) :1691-1704
[6]   E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases [J].
Babiker, Hani M. ;
Byron, Sara A. ;
Hendricks, William P. D. ;
Elmquist, William F. ;
Gampa, Gautham ;
Vondrak, Jessica ;
Aldrich, Jessica ;
Cuyugan, Lori ;
Adkins, Jonathan ;
De Luca, Valerie ;
Tibes, Raoul ;
Borad, Mitesh J. ;
Marceau, Katie ;
Myers, Thomas J. ;
Paradiso, Linda J. ;
Liang, Winnie S. ;
Korn, Ronald L. ;
Cridebring, Derek ;
Von Hoff, Daniel D. ;
Carpten, John D. ;
Craig, David W. ;
Trent, Jeffrey M. ;
Gordon, Michael S. .
INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) :636-645
[7]   Investigational antiviral drugs for the treatment of COVID-19 patients [J].
Beheshtirouy, Samineh ;
Khani, Elnaz ;
Khiali, Sajad ;
Entezari-Maleki, Taher .
ARCHIVES OF VIROLOGY, 2022, 167 (03) :751-805
[8]   The molecular structure of penicillin [J].
Bentley, R .
JOURNAL OF CHEMICAL EDUCATION, 2004, 81 (10) :1462-1470
[9]   Use Your Words Carefully: What is a Chronic Disease? [J].
Bernell, Stephanie ;
Howard, Steven W. .
FRONTIERS IN PUBLIC HEALTH, 2016, 4
[10]   Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors A Randomized Clinical Trial [J].
Blayney, Douglas W. ;
Mohanlal, Ramon ;
Adamchuk, Hryhoriy ;
Kirtbaya, Dmitry Valikovich ;
Chen, Michael ;
Du, Lihua ;
Ogenstad, Stephan ;
Ginn, Greg ;
Huang, Lan ;
Zhang, Qingyuan .
JAMA NETWORK OPEN, 2022, 5 (01)